BTK inhibitor selection for chronic lymphocytic leukemia: which drug for which patient?
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2022.2074393
Abstract: ABSTRACT Introduction The development of BTK inhibitors has revolutionized the management of CLL. Currently, there are 3 BTK inhibitors available to treat CLL: ibrutinib, acalabrutinib, and zanubrutinib (the latter not yet approved for this disease… read more here.
Keywords: patient; btk inhibitor; inhibitor selection; btk ... See more keywords